A study published in the journal 'Nature Biotechnology' presents an innovative neurotechnology based on graphene with the potential for transformative impact in neuroscience and medical applications. This research, led by the Catalan Institute of Nanoscience and Nanotechnology (ICN2), is being developed for therapeutic applications through the spin-off company INBRAIN Neuroelectronics, member of CataloniaBio & HealthTech. 

The Viladecans facilities of Alcura Health Spain, member of CataloniaBio & HealthTech, obtained the Manufacturer Import Authorization (MIA) granted by the Spanish Agency of Medicines and Medical Devices (AEMPS), which allows the import and release of products associated with gene, cellular, and tissue engineering therapies, also known as ATMP (Advanced Therapy Medicine Products). This authorization makes the Viladecans facilities in Barcelona the first center in the entire international Cencora network to have this authorization. 

BHV Partners, member of CataloniaBio & HealthTech, has appointed entrepreneur Albert Mascarell as its new CEO, effective January 1, 2024. 

XRHealth, the leading healthcare platform in Spatial computing, announced that the company secured $6 million in funding led by Asabys Partners, with the participation of NOVA Prime Fund, a venture capital fund created by global innovator LG Electronics and Clearbrook, LLC., and XRHealth’s current investors.

The call for the tenth edition of theBioèxit Award of the year, promoted by CataloniaBio & HealthTech, hasopened today. The 2024 edition will mark the tenth year of recognising the bestbusiness awards in the health sector in Catalonia, a sign that it is one of theleading European hubs for research and innovation in health.

The CataloniaBio & HealthTech board and team wish you all a Happy New Year 2024, and especially to the more than 225 members of the association, its collaborators and healthcare and life sciences professionals. This is a good time to look back and share the main milestones and the work we have carried out during this year 2023.

HumanITcare and VitalAire Brazil are using Garmin wearables to help revolutionise remote monitoring of patients who rely on long-term oxygen therapy, potentially resulting in timely interventions and personalised care; all from the comfort of patients’ homes.

What resources do we have to protect innovation in the health sector? We are very familiar with the patent system, but the 2016 EU Trade Secrets Directive has unified and strengthened the protection of trade secrets, providing legal tools and remedies similar to other intellectual property rights.

Almirall, member of CataloniaBio & HealthTech, continues its inorganic growth strategy to enhance its portfolio of dermatological products. The pharmaceutical company of the Gallardo family has reached an agreement with the Belgian firm Etherna to use its RNA technology and develop products for serious skin diseases, including non-melanoma skin cancer. The agreement includes an initial payment, the amount of which has not been disclosed but sources close to the operation assure that it is not significant, and a potential payment of over 300 million euros if a product reaches the market. 

Around thirty CEOs from CataloniaBio & HealthTech met on Tuesday 13 December at the HUB cambraDigital (Barcelona Chamber of Commerce) for the fifth edition of the CEO Council this 2023. The special guest at this last event of the year was Javier Ponce, Director General of the CDTI. The welcome was given by Joan Puig de Dou, CEO of Kymos and President of CataloniaBio & HealthTech.

Leanbio, member of CataloniaBio & HealthTech, adds 20 million euros of investment to its plant, currently on construction, in Sant Quirze del Vallès (Barcelona), which will become one of the most advanced in Europe. The company, based at the Barcelona Science Park, is expanding its production capacity in response to a growing demand for global projects, and has already secured licensing agreements for biosimilars with major multinational companies in the sector. 

El Vall d'Hebron Institut de Recerca (VHIR) i ZeClinics, ambdós membres de CataloniaBio & HealthTech, treballen conjuntament en el projecte NanoDIRE-CT, l'objectiu del qual és utilitzar un mètode innovador basat en nanocossos, és a dir, fragments d'anticossos de mida petita, per a la teràpia dirigida de cèl·lules mare tumorals.

The Scientific Group, a leader in the IVD industry, and Inbiomotion, member of CataloniaBio & HealthTech, a company commercializing its proprietary MAF Test® for identifying high risk early-stage breast cancer patients have signed an agreement to start marketing MAF Test® in Sub-Saharan Africa.

Inbrain Neuroelectronics has secured a loan from the European Investment Bank (EIB) for a total of 20 million euros. The biotech, member of CataloniaBio & HealthTech, led by Carolina Aguilar, will be able to advance the clinical development of its neurology R&D programmes for diseases such as Parkinson's disease, epilepsy and speech disorders.

Two of the five European companies awarded for their innovation by the European Commission (EC) are from Catalonia. These companies are Zymvol and MJN, both CataloniaBio & HealthTech members, and both recognized under the Innovation Radar Prize 2023 program organized by the European Comission and the Dealflow.eu platform. This platform identifies high-potential innovative projects among all companies that have access to European funds.

IMIDomics, a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), a CataloniaBio & HealthTech member, announced that it is expanding its strategic collaboration with Bristol Myers Squibb, a global biopharmaceutical company. This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.

CataloniaBio & HealthTech, conjuntament amb Kymos i LeanBox, han organitzat aquest dimarts 28 de novembre un workshop per compartir coneixements sobre com es pot aplicar la metodologia Lean als laboratoris del sector salut. La sessió ha comptat amb una taula rodona i una part més pràctica, s’ha celebrat a la seu de Kymos Group al Parc Tecnològic de Cerdanyola del Vallès, amb totes les places esgotades; hi ha participat 40 persones, procedents de 22 empreses i institucions.

Trifermed, a corporate strategy and business development firm in the health sector, and a CataloniaBio & HealthTech member, announced its expansion into North America. The company will open its headquarters in Boston, Massachusetts, and a representative office in Montreal, Canada. This expansion is a crucial part of trifermed’s strategy to extend its global influence in Biopharmaceuticals, MedTech, and Digital Health. 

ALLOX, a techbio company, announced its incorporation, as well as the successful closing of an undisclosed pre-seed financing from Asabys new fund Sabadell Asabys II. The fund has backed the company and will join a future round involving local and international investors. 

Fertypharm, member of CataloniaBio & HealthTech announces the launch of their products FertyBiotic Mulher, FertyBiotic Homem, and FertyBiotic Gravidez in Portugal this January 2024. First steps involve forging new partnerships with A. Sousa & C.ª Lda - Pharmaceutical full-line wholesaler.